Risankizumab for Ulcerative Colitis

Overview of attention for article published in JAMA: Journal of the American Medical Association, September 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 23 news outlets
blogs: 1 blog
twitter: 65 X users
patent: 2 patents
facebook: 1 Facebook page

reddit: 1 Redditor
video: 1 YouTube creator
guideline: 3 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 106 Mendeley

So far, Altmetric has seen 23 news stories from 23 outlets.

Colite Ulcerosa attiva da moderata a severa: Risankizumab (SKYRIZI*) ottiene la rimborsabilità da AIFA

saluteh24, 27 Aug 2026

AbbVie, azienda biofarmaceutica globale basata sulla ricerca, annuncia che l’Agenzia Italiana del Farmaco (AIFA) ha approvato…

‘More options’ flood IBD market as rival IL-23 drugs face off with Stelara biosimilar boom

Healio.com, 14 May 2025

A seismic shift is underway for inflammatory bowel disease therapies as a trio of newly approved interleukin-23 inhibitors are…

AbbVie’s SKYRIZI® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis

PharmiWeb, 13 Jan 2025

PRESS RELEASE – For UK consumer health, medical and trade media only Risankizumab will be available on the NHS in Scotland for…

Ulcerative colitis treatment recommended by NICE

Pf Media, 28 Aug 2024

The National Institute for Health and Care Excellence (NICE) has issued final Technology Appraisal Guidance (TAG) recommending…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 19 additional news stories.